Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
3
50%
Ph not_applicable
1
17%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Other(3)

Detailed Status

unknown3
Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
N/A1 (16.7%)

Trials by Status

completed233%
unknown350%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingnot_applicable

Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma

NCT07727642
completedphase_1

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

NCT05206019
completedphase_3

Test Albuvirtide in Experienced Patients

NCT02369965
unknownphase_2

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

NCT03719664
unknownphase_2

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

NCT04560569
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07727642Not Applicable

Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma

Recruiting
NCT05206019Phase 1

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

Completed
NCT02369965Phase 3

Test Albuvirtide in Experienced Patients

Completed
NCT03719664Phase 2

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Unknown
NCT04560569Phase 2

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Unknown
NCT04819347Phase 2

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6